Top
image credit: Unsplash

With FDA verging on its first COVID booster approval, Pfizer and Moderna will have to recalibrate revenues—again

August 12, 2021

Category:

Pfizer and Moderna are getting used to readjusting their projected COVID-19 vaccine sales. Now another recalibration may be in order.

The FDA is set to authorize a third dose of their COVID-19 shots for those with weakened immune systems, NBC News reports.

The agency’s decision for immunocompromised people, who do not mount an effective response to the currently authorized two-dose regimens from Pfizer and Moderna, could be a precursor to approvals for the elderly and then for other segments of the population to receive a third dose. For these individuals, the reason to vaccinate again would be because the protection they received from the first two doses may wane over time.

Read More on FiercePharma